Routine Gene Testing Advised To Guide Colorectal Cancer Treatment
This article was originally published in The Gray Sheet
The American Society of Clinical Oncology Jan. 13 recommended that physicians treating metastatic colorectal cancer patients who are candidates for drugs such as ImClone's Erbitux (cetuximab) or Amgen's Vectibix (panitumumab) first be tested for KRASgene mutations
You may also be interested in...
The laboratory industry, facing policy pressures, commissioned a study by Battelle Memorial Institute that finds that genetic testing is adding thousands of jobs and $16.5 billion annually to the U.S. economy.
Personalized medicine company DxS is preparing a PMA application for a companion diagnostic to Amgen's colorectal cancer drug Vectibix, supported by clinical utility data from a recent Amgen-sponsored clinical trial, according to DxS CEO Stephen Little
As Europe’s health emergency body HERA approaches its first anniversary, an unprecedented range of stakeholders including industry bodies will be meeting in December to discuss HERA’s achievements, while a separate event will showcase the next generation of vaccines for COVID-19 and other infections.